
Idexx Laboratories ownership: holders and insider trading
$704.23+0.89%Close 13 Nov 2026 · Market value $55.66B
As filed, its directors and officers own 0.8% of the shares (proxy statement, 8 Mar 2026); 1,286 institutional managers reported holding 93.8% at 30 Jun 2026. Over the last twelve months, insiders sold $58.43M of shares on the open market, and bought none.
From the company's proxy statement, each holder's latest Schedule 13D or 13G, the institutional managers' quarterly 13F reports and the insiders' Form 4 filings. A percentage is shown as filed; one marked * is worked out here from the shares outstanding.
Largest holders
| Holder | Type | Shares | Of the company | Source | As of |
|---|
| Vanguard | Institution | 9.9M | 12.54%* | Form 13F | 30 Jun 2026 |
|---|
| BlackRock | Institution | 8.2M | 10.37%* | Form 13F | 30 Jun 2026 |
|---|
| Vanguard Capital Management | Holder | 6.0M | 7.51% | Schedule 13G | 31 Mar 2026 |
|---|
| Vanguard Portfolio Management | Holder | 4.0M | 5.04% | Schedule 13G | 30 Sep 2026 |
|---|
| State Street | Institution | 3.7M | 4.76%* | Form 13F | 30 Jun 2026 |
|---|
| Invesco | Institution | 3.6M | 4.58%* | Form 13F | 30 Jun 2026 |
|---|
| Geode Capital Management | Institution | 2.6M | 3.25%* | Form 13F | 30 Jun 2026 |
|---|
| Bamco Inc | Institution | 2.0M | 2.51%* | Form 13F | 30 Jun 2026 |
|---|
| Morgan Stanley | Institution | 1.4M | 1.72%* | Form 13F | 30 Jun 2026 |
|---|
| UBS | Institution | 1.3M | 1.62%* | Form 13F | 30 Jun 2026 |
|---|
| BNY | Institution | 1.2M | 1.51%* | Form 13F | 30 Jun 2026 |
|---|
| Arrowstreet Capital, Limited Partnership | Institution | 1.1M | 1.35%* | Form 13F | 30 Jun 2026 |
|---|
| Fundsmith LLP | Institution | 1.0M | 1.29%* | Form 13F | 30 Jun 2026 |
|---|
| Blair William & Co | Institution | 919K | 1.17%* | Form 13F | 30 Jun 2026 |
|---|
| Northern Trust | Institution | 918K | 1.17%* | Form 13F | 30 Jun 2026 |
|---|
| Fidelity (FMR) | Institution | 823K | 1.04%* | Form 13F | 30 Jun 2026 |
|---|
| American Century Companies Inc | Institution | 808K | 1.03%* | Form 13F | 30 Jun 2026 |
|---|
| Capital Group | Institution | 789K | 1.00%* | Form 13F | 30 Jun 2026 |
|---|
| JPMorgan Chase | Institution | 756K | 0.96%* | Form 13F | 30 Jun 2026 |
|---|
| Principal Financial Group Inc | Institution | 743K | 0.94%* | Form 13F | 30 Jun 2026 |
|---|
Insider transactions latest 25
| Insider | Date | Transaction | Shares | Price | Value |
|---|
| FENNELL GEORGE · Executive Vice President | 10 Nov 2026 | Option exercise | +706 | $141.60 | $99.97K |
|---|
| FENNELL GEORGE · Executive Vice President | 10 Nov 2026 | Option exercise | +560 | $178.26 | $99.83K |
|---|
| FENNELL GEORGE · Executive Vice President | 10 Nov 2026 | Option exercise | +483 | $206.94 | $99.95K |
|---|
| Underberg Sharon E. · EVP, GC & Corporate Secretary | 4 Nov 2026 | Option exercise | +8.9K | $288.78 | $2.57M |
|---|
| Underberg Sharon E. · EVP, GC & Corporate Secretary | 4 Nov 2026 | Open-market sale | −6.3K | $688.25 | $4.37M |
|---|
| Underberg Sharon E. · EVP, GC & Corporate Secretary | 4 Nov 2026 | Open-market sale | −1.5K | $689.05 | $1.04M |
|---|
| Underberg Sharon E. · EVP, GC & Corporate Secretary | 4 Nov 2026 | Open-market sale | −1.1K | $690.02 | $728.0K |
|---|
| MAZELSKY JONATHAN JAY · Executive Chair of the Board · Director | 4 Nov 2026 | Option exercise | +25.1K | $178.26 | $4.48M |
|---|
| MAZELSKY JONATHAN JAY · Executive Chair of the Board · Director | 4 Nov 2026 | Open-market sale | −1.9K | $698.26 | $1.36M |
|---|
| MAZELSKY JONATHAN JAY · Executive Chair of the Board · Director | 4 Nov 2026 | Open-market sale | −4.1K | $699.33 | $2.85M |
|---|
| MAZELSKY JONATHAN JAY · Executive Chair of the Board · Director | 4 Nov 2026 | Open-market sale | −1.7K | $700.33 | $1.17M |
|---|
| MAZELSKY JONATHAN JAY · Executive Chair of the Board · Director | 4 Nov 2026 | Open-market sale | −4.5K | $701.36 | $3.18M |
|---|
| MAZELSKY JONATHAN JAY · Executive Chair of the Board · Director | 4 Nov 2026 | Open-market sale | −2.1K | $702.21 | $1.50M |
|---|
| MAZELSKY JONATHAN JAY · Executive Chair of the Board · Director | 4 Nov 2026 | Open-market sale | −4.0K | $703.45 | $2.78M |
|---|
| MAZELSKY JONATHAN JAY · Executive Chair of the Board · Director | 4 Nov 2026 | Open-market sale | −240 | $705.59 | $169.3K |
|---|
| MAZELSKY JONATHAN JAY · Executive Chair of the Board · Director | 4 Nov 2026 | Open-market sale | −840 | $707.00 | $593.9K |
|---|
| MAZELSKY JONATHAN JAY · Executive Chair of the Board · Director | 4 Nov 2026 | Open-market sale | −1.8K | $707.84 | $1.30M |
|---|
| MAZELSKY JONATHAN JAY · Executive Chair of the Board · Director | 4 Nov 2026 | Open-market sale | −1.3K | $709.00 | $921.7K |
|---|
| MAZELSKY JONATHAN JAY · Executive Chair of the Board · Director | 4 Nov 2026 | Open-market sale | −1.5K | $710.12 | $1.07M |
|---|
| MAZELSKY JONATHAN JAY · Executive Chair of the Board · Director | 4 Nov 2026 | Open-market sale | −775 | $711.31 | $551.3K |
|---|
| MAZELSKY JONATHAN JAY · Executive Chair of the Board · Director | 4 Nov 2026 | Open-market sale | −331 | $711.95 | $235.7K |
|---|
| Lane Michael · Executive Vice President | 4 Nov 2026 | Open-market sale | −243 | $687.85 | $167.1K |
|---|
| Lane Michael · Executive Vice President | 4 Nov 2026 | Open-market sale | −2.1K | $689.70 | $1.42M |
|---|
| Lane Michael · Executive Vice President | 4 Nov 2026 | Open-market sale | −1.7K | $687.46 | $1.15M |
|---|
| JUNIUS DANIEL M · Director | 4 Nov 2026 | Open-market sale | −700 | $705.78 | $494.0K |
|---|
Form 4 filings since 16 Nov 2024: purchases and sales, grants, option exercises and shares withheld for tax. Gifts and other transfers are left out.
IDXX in the terminal
Holders over eight quarters by family, every Form 4 and Form 144 back two years, and alerts on insider buying.